Acute Lymphoblastic Leukemia Specialty Channel

Acute Lymphoblastic Leukemia

Specialty Channel

Conference Coverage

Utilizing Immunotherapies for Optimal Treatment of Ph-Positive Acute Lymphoblastic Leukemia

06/29/2025

Elias Jabbour, MD

At the 2025 Great Debates in Hematologic Malignancies meeting, Elias Jabbour, MD, participated in a debate on the optimal regimen for treating Ph-positive ALL, highlighting the benefits of utilizing immunotherapies.

At the 2025 Great Debates in...

06/29/2025

Oncology

Conference Coverage

Benefits of Chemotherapy Plus Allogeneic Stem Cell Transplantation as Treatment Strategy for Ph-Positive ALL

06/28/2025

Shira Dinner, MD

Shira Dinner, MD, debates the benefits of chemotherapy followed by allogeneic stem cell transplantation among patients with Philadelphia chromosome-positive acute lymphoblastic leukemia at the 2025 Great Debates in Hematologic Malignancies.

Shira Dinner, MD, debates the...

06/28/2025

Oncology

Quiz

Autologous Hematopoietic Stem Cell Transplant for Ph-Negative ALL

05/27/2025

In a retrospective study assessing autologous hematopoietic stem cell transplantation for patients with Philadelphia chromosome-negative acute lymphoblastic leukemia, which patient subgroup demonstrated superior leukemia-free survival at 5...

In a retrospective study...

05/27/2025

Oncology

News

Autologous Hematopoietic Stem Cell Transplant Shows Safety for Late Treatment Intensification for Ph-Negative ALL

05/16/2025

Emily Estrada

Autologous hematopoietic stem cell transplantation demonstrated relative safety for patients with Philadelphia chromosome-negative acute lymphoblastic leukemia, according to a recent study.

Autologous hematopoietic stem...

05/16/2025

Oncology

Quiz

Efficacy of Inaticabtagene Autoleucel for B-ALL

05/05/2025

What was the overall response rate observed at month 3 following treatment with inaticabtagene autoleucel in a phase 2 trial among patients with R/R B-cell acute lymphoblastic leukemia?

What was the overall response...

05/05/2025

Oncology

News

Dasatinib Plus CAR T-Cell Therapy Shows Encouraging Efficacy for Patients With Newly Diagnosed Ph-Positive ALL

04/29/2025

Emily Estrada

For patients with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia, dasatinib plus sequential CD19-CD22 CAR T-cell therapy demonstrated improved outcomes and high rates of complete molecular remission.

For patients with newly...

04/29/2025

Oncology

Quiz

Inaticabtagene Autoleucel Therapy for R/R B-ALL

04/21/2025

Regarding the durability of remission achieved with inaticabtagene autoleucel therapy among patients with R/R B-ALL in a phase 2 trial, what was the median duration of remission reported?

Regarding the durability of...

04/21/2025

Oncology

News

Inaticabtagene Autoleucel Demonstrates Efficacy and Tolerability for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

03/25/2025

Emily Estrada

Inaticabtagene autoleucel treatment for patients with relapsed/refractory B-cell acute lymphoblastic leukemia showed efficacy and durability in a phase 2 clinical trial.

Inaticabtagene autoleucel...

03/25/2025

Oncology

News

Durability and Tolerability of Obecabtagene Autoleucel CAR-T Therapy for R/R B-Cell Acute Lymphoblastic Leukemia

02/07/2025

Emily Estrada

For patients with relapsed/refractory B-cell acute lymphoblastic leukemia, obecabtagene autoleucel anti-CD19 CAR-T therapy showed promising durability and tolerability, according to a recent study.

For patients with...

02/07/2025

Oncology

News

FDA Approves Oral Formulation of Imatinib for Patients With Certain Leukemias and Gastrointestinal Tumors

11/25/2024

Stephanie Holland

The FDA has approved an advanced liquid formulation of imatinib for patients with certain leukemias and gastrointestinal tumors to increase dosing accuracy.

The FDA has approved an advanced...

11/25/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Conference Coverage

Utilizing Immunotherapies for Optimal Treatment of Ph-Positive Acute Lymphoblastic Leukemia

06/29/2025

Elias Jabbour, MD

At the 2025 Great Debates in...

06/29/2025

Oncology

Conference Coverage

Benefits of Chemotherapy Plus Allogeneic Stem Cell Transplantation as Treatment Strategy for Ph-Positive ALL

06/28/2025

Shira Dinner, MD

Shira Dinner, MD, debates the...

06/28/2025

Oncology

News

Autologous Hematopoietic Stem Cell Transplant Shows Safety for Late Treatment Intensification for Ph-Negative ALL

05/16/2025

Emily Estrada

Autologous hematopoietic stem cell transplantation demonstrated relative safety for patients with Philadelphia chromosome-negative acute lymphoblastic leukemia, according to a recent study.

Autologous hematopoietic stem...

05/16/2025

Oncology

News

Dasatinib Plus CAR T-Cell Therapy Shows Encouraging Efficacy for Patients With Newly Diagnosed Ph-Positive ALL

04/29/2025

Emily Estrada

For patients with newly...

04/29/2025

Oncology

News

Inaticabtagene Autoleucel Demonstrates Efficacy and Tolerability for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

03/25/2025

Emily Estrada

Inaticabtagene autoleucel treatment for patients with relapsed/refractory B-cell acute lymphoblastic leukemia showed efficacy and durability in a phase 2 clinical trial.

Inaticabtagene autoleucel...

03/25/2025

Oncology

News

Durability and Tolerability of Obecabtagene Autoleucel CAR-T Therapy for R/R B-Cell Acute Lymphoblastic Leukemia

02/07/2025

Emily Estrada

For patients with relapsed/refractory B-cell acute lymphoblastic leukemia, obecabtagene autoleucel anti-CD19 CAR-T therapy showed promising durability and tolerability, according to a recent study.

For patients with...

02/07/2025

Oncology

News

FDA Approves Oral Formulation of Imatinib for Patients With Certain Leukemias and Gastrointestinal Tumors

11/25/2024

Stephanie Holland

The FDA has approved an advanced liquid formulation of imatinib for patients with certain leukemias and gastrointestinal tumors to increase dosing accuracy.

The FDA has approved an advanced...

11/25/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Blinatumomab Added to Consolidation Chemotherapy Improves Overall Survival Among Patients in MRD-Negative Remission From B-Cell Precursor ALL

08/14/2024

Amber Denham

According to a phase 3 study, the addition of blinatumomab to consolidation chemotherapy for adult patients in measurable residual disease-negative remission from B-cell precursor acute lymphoblastic leukemia significantly improved overall...

According to a phase 3 study,...

08/14/2024

Oncology

News

FDA Grants Approval to Blinatumomab Consolidation Therapy for CD19-Positive Philadelphia Chromosome-Negative B-cell Precursor ALL

06/21/2024

The FDA granted approval to blinatumomab for adult and pediatric patients with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multi-phase chemotherapy.

The FDA granted approval to...

06/21/2024

Oncology

Interactive Features

Quiz

Autologous Hematopoietic Stem Cell Transplant for Ph-Negative ALL

05/27/2025

In a retrospective study...

05/27/2025

Oncology

Quiz

Efficacy of Inaticabtagene Autoleucel for B-ALL

05/05/2025

What was the overall response rate observed at month 3 following treatment with inaticabtagene autoleucel in a phase 2 trial among patients with R/R B-cell acute lymphoblastic leukemia?

What was the overall response...

05/05/2025

Oncology

Quiz

Inaticabtagene Autoleucel Therapy for R/R B-ALL

04/21/2025

Regarding the durability of remission achieved with inaticabtagene autoleucel therapy among patients with R/R B-ALL in a phase 2 trial, what was the median duration of remission reported?

Regarding the durability of...

04/21/2025

Oncology

Quiz

Efficacy of Imatinib vs Dasatinib Prophylaxis Among Patients With Philadelphia-Positive ALL Following ASCT

04/02/2024

Oncology

Quiz

R/R Pre-B ALL Treatment With Mini-Hyper CVD Chemotherapy Plus Inotuzumab Ozogamicin With or Without Blinatumomab

08/01/2023

True or False: A treatment regimen of low-intensity mini-hyper CVD plus inotuzumab and blinatumomab demonstrated improved survival outcomes among patients with R/R Philadelphia chromosome-negative CD22-positive pre-B ALL.

True or False: A treatment...

08/01/2023

Oncology

Quiz

Quiz: Use of Inotuzumab Ozogamicin Induction Therapy for De Novo Acute B-Lymphoblastic Leukemia

03/01/2023

True or False: 3 cycles of inotuzumab ozogamicin induction therapy showed promising remission rates in patients aged >55 years with de novo acute B-lymphoblastic leukemia, according to findings from a recent trial.

True or False: 3 cycles of...

03/01/2023

Oncology

Quiz

Use of Blinatumomab During Consolidation for High-Risk Ph-Negative B-Cell Precursor ALL

03/01/2023

True or False: The use of blinatumomab during consolidation for high-risk Philadelphia chromosome negative B-Cell precursor acute lymphoblastic leukemia was associated with reduced relapse rates, according to findings from a recent trial.

True or False: The use of...

03/01/2023

Oncology

Quiz

Quiz: ASCT From Matched Sibling Donors vs Matched Unrelated Donors in Adult High-Risk ALL

10/05/2022

True or False: Allogeneic hematopoietic stem cell transplantations from matched sibling donors and matched unrelated donors yielded similar long-term outcomes for patients with BCR-ABL-negative ALL.

True or False: Allogeneic...

10/05/2022

Oncology

Quiz

Quiz: Complete Remission Rate Among Patients With R/R B-Cell ALL With Anti-CD19 CAR T-Cell Therapy

08/23/2022

True or false: The complete remission rate was higher among patients with relapsed/refractory B-cell ALL with lower (rather than with higher) tumor burden receiving treatment with anti-CD19 CAR T-cell therapy.

True or false: The complete...

08/23/2022

Oncology

Quiz

Quiz: Patients With ALL Are More Likely to Receive Salvage Chemotherapy After Treatment With Which Prior Therapy?

08/05/2022

True or False: Findings from the phase 3 INO-VATE trial revealed that patients with relapsed/refractory ALL who received inotuzumab ozogamicin were less likely to receive subsequent salvage therapy than those who received standard...

True or False: Findings from the...

08/05/2022

Oncology

Recent News

News

Autologous Hematopoietic Stem Cell Transplant Shows Safety for Late Treatment Intensification for Ph-Negative ALL

05/16/2025

Emily Estrada

Autologous hematopoietic stem cell transplantation demonstrated relative safety for patients with Philadelphia chromosome-negative acute lymphoblastic leukemia, according to a recent study.

Autologous hematopoietic stem...

05/16/2025

Oncology

News

Dasatinib Plus CAR T-Cell Therapy Shows Encouraging Efficacy for Patients With Newly Diagnosed Ph-Positive ALL

04/29/2025

Emily Estrada

For patients with newly...

04/29/2025

Oncology

News

Inaticabtagene Autoleucel Demonstrates Efficacy and Tolerability for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

03/25/2025

Emily Estrada

Inaticabtagene autoleucel treatment for patients with relapsed/refractory B-cell acute lymphoblastic leukemia showed efficacy and durability in a phase 2 clinical trial.

Inaticabtagene autoleucel...

03/25/2025

Oncology

News

Durability and Tolerability of Obecabtagene Autoleucel CAR-T Therapy for R/R B-Cell Acute Lymphoblastic Leukemia

02/07/2025

Emily Estrada

For patients with relapsed/refractory B-cell acute lymphoblastic leukemia, obecabtagene autoleucel anti-CD19 CAR-T therapy showed promising durability and tolerability, according to a recent study.

For patients with...

02/07/2025

Oncology

News

FDA Approves Oral Formulation of Imatinib for Patients With Certain Leukemias and Gastrointestinal Tumors

11/25/2024

Stephanie Holland

The FDA has approved an advanced liquid formulation of imatinib for patients with certain leukemias and gastrointestinal tumors to increase dosing accuracy.

The FDA has approved an advanced...

11/25/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Blinatumomab Added to Consolidation Chemotherapy Improves Overall Survival Among Patients in MRD-Negative Remission From B-Cell Precursor ALL

08/14/2024

Amber Denham

According to a phase 3 study,...

08/14/2024

Oncology

News

FDA Grants Approval to Blinatumomab Consolidation Therapy for CD19-Positive Philadelphia Chromosome-Negative B-cell Precursor ALL

06/21/2024

The FDA granted approval to...

06/21/2024

Oncology

News

Mini-Hyper-CVD Plus Venetoclax Yields Safety and Activity Among Patients With Heavily Pretreated R/R ALL

04/09/2024

Jordan Kadish

According to a phase 1/2 trial, combining mini-hyper-CVD low-intensity chemotherapy with venetoclax yielded safety and activity among patients with heavily pretreated R/R acute lymphoblastic leukemia.

According to a phase 1/2 trial,...

04/09/2024

Oncology

News

Allogeneic Stem Cell Transplantation in First Complete Remission for Patients With Philadelphia Chromosome-Positive ALL

04/01/2024

Jordan Kadish

Patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who received allogeneic stem cell transplantation in the first complete remission demonstrated superior survival outcomes compared with patients who did not undergo...

Patients with Philadelphia...

04/01/2024

Oncology

News

Genotype-Guided Therapy Demonstrates High Response and Survival Rates for Patients With R/R DLBCL

09/26/2025

Emily Estrada

The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.

The implementation of R-ICE...

09/26/2025

Oncology

News

PD-1/PD-L1 Inhibitor Monotherapy Demonstrates Accceptable Safety, Limited Efficacy for R/R DLBCL

09/26/2025

Emily Estrada

Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.

Treatment of R/R diffuse large...

09/26/2025

Oncology

News

Polatuzumab-Based Regimens Demonstrate Promising Efficacy for R/R DLBCL Compared to Traditional Salvage Therapies

09/26/2025

Emily Estrada

Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.

Compared with traditional...

09/26/2025

Oncology

FDA Approval

FDA Approves Imlunestrant for Patients With ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer

09/25/2025

Stephanie Holland

The FDA has approved imlunestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations.

The FDA has approved...

09/25/2025

Oncology

News

Pexidartinib Shows Durable Response Among Patients with Tenosynovial Giant Cell Tumors

09/25/2025

Allison Casey

Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.

Pexidartinib showed sustained...

09/25/2025

Oncology

News

Clarithromycin-Based Quadruplet Therapy Demonstrates Promising Clinical Responses for Treatment of Relapsed/Refractory Multiple Myeloma

09/24/2025

Emily Estrada

For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.

For patients with...

09/24/2025

Oncology

News

First-Line mFOLFIRINOX, S-IROX Fail to Improve Survival Among Patients With Recurrent or Metastatic Pancreatic Cancer

09/23/2025

Stephanie Holland

Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...

Results from the phase 2/3...

09/23/2025

Oncology

News

Novel Anti-CSF1 Receptor Antibody for Patients With Tenosynovial Giant Cell Tumor

09/23/2025

Allison Casey

According to a phase 2a trial, the novel anti-CSF1 receptor monoclonal antibody, AMB-05X, was found to have favorable pharmacokinetics, pharmacodynamics, efficacy, and safety among patients with tenosynovial giant cell tumors.

According to a phase 2a trial,...

09/23/2025

Oncology

News

Adverse Events With Pexidartinib for Patients With Tenosynovial Giant Cell Tumor

09/23/2025

Allison Casey

According to an analysis of the FDA Adverse Events Reporting System (FAERS) database, the overall safety profile of pexidartinib was generally consistent with the clinical trial findings.

According to an analysis of the...

09/23/2025

Oncology

News

Trifluridine/Tipiracil Plus Bevacizumab Escalation Demonstrates Promise Among Patients With Advanced or Unresectable Metastatic Colorectal Cancer

09/22/2025

Stephanie Holland

According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...

According to results from the...

09/22/2025

Oncology